Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

Patricia Sancho Andrés

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1092-5395; OpenAlex author ID A5037568446. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 4 papers · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 20

  1. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  2. PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-24-3475↗
  3. Physico-chemical characterization of the tumour microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejcb.2024.151396↗
  4. Fatty acid oxidation is critical for the tumorigenic potential and chemoresistance of pancreatic cancer stem cells. Last author DOI 10.1186/s12967-024-05598-6↗
  5. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.biopha.2022.114162↗
  6. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  7. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
  8. PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer Last author DOI 10.1101/2021.11.15.468579↗
  9. Inhibition of Mitochondrial Dynamics Preferentially Targets Pancreatic Cancer Cells with Enhanced Tumorigenic and Invasive Potential. Last author DOI 10.3390/cancers13040698↗
  10. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. First author DOI 10.1038/s41467-020-16395-2↗
  11. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Co-author DOI 10.1038/s41467-020-18954-z↗
  12. Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification. Last author DOI 10.3390/jcm9124128↗
  13. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. Last author DOI 10.4252/wjsc.v12.i11.1410↗
  14. The ever-changing landscape of pancreatic cancer stem cells. Co-author DOI 10.1016/j.pan.2016.04.004↗
  15. More challenges ahead-metabolic heterogeneity of pancreatic cancer stem cells. First author DOI 10.1080/23723556.2015.1105353↗
  16. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Co-author DOI 10.1016/j.cmet.2015.08.015↗
  17. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Co-author DOI 10.1136/gutjnl-2014-308935↗
  18. Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. Co-author DOI 10.3791/52801↗
  19. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. First author DOI 10.1053/j.gastro.2014.08.002↗
  20. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. Co-author DOI 10.1371/journal.pone.0076518↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher Heeschen · 15 shared papers, 2013–2025 · strength 1.60
  2. Bruno Sáinz · 13 shared papers, 2014–2026 · strength 1.39
  3. Sonia Alcalá · 9 shared papers, 2015–2026 · strength 1.04
  4. Beatriz Parejo-Alonso · 6 shared papers, 2020–2026 · strength 0.94
  5. Sarah Courtois · 6 shared papers, 2020–2025 · strength 0.93
  6. Pilar Espiau-Romera · 5 shared papers, 2020–2025 · strength 0.81
  7. Petra Jagušt · 6 shared papers, 2015–2025 · strength 0.78
  8. Patrick Christian Hermann · 6 shared papers, 2014–2023 · strength 0.45
  9. Sara Maria David Trabulo · 4 shared papers, 2013–2025 · strength 0.43
  10. Julie Earl · 3 shared papers, 2020–2026 · strength 0.42
  11. Quan Zheng · 3 shared papers, 2021–2025 · strength 0.42
  12. Juan Carlos López-Gil · 2 shared papers, 2023–2026 · strength 0.33
  13. Sandra Valle · 3 shared papers, 2020–2023 · strength 0.30
  14. Paola Martinelli · 3 shared papers, 2014–2023 · strength 0.25
  15. Mariano Barbacid · 2 shared papers, 2014–2026 · strength 0.24
  16. Carmen E. Guerra · 2 shared papers, 2014–2026 · strength 0.24
  17. Jiajia Tang · 2 shared papers, 2021–2023 · strength 0.24
  18. Manuel M. Hidalgo · 3 shared papers, 2013–2023 · strength 0.22
  19. Alfredo Carrato Mena · 2 shared papers, 2020–2023 · strength 0.21
  20. Antonio Agostini · 1 shared paper, 2026 · strength 0.21
  21. Lívia Archibugi · 1 shared paper, 2026 · strength 0.21
  22. Pilar Acedo Núñez · 1 shared paper, 2026 · strength 0.21
  23. Ana Galván-del-Rey · 1 shared paper, 2026 · strength 0.21
  24. Claudio Luchini · 1 shared paper, 2026 · strength 0.21
  25. Gabriele Capurso · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.